Navigation Links
Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
Date:12/3/2008

radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD(TM) and LungCAD(TM) software use an advanced CAD algorithm to analyze CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualization platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programs worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.

About Medicsig
'/>"/>

SOURCE Medicsight PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. MGT Capital Investments, Inc. is Delighted with the Announcement of Medicsights Commercial Agreement with Toshiba PACS Division
2. Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser
3. Medicsight ColonCAD Technology Successfully Identified Cancer in 100% of Patients Included in Data Presented at ESGAR 2008
4. Medicsight Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008
5. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
6. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
7. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
8. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
9. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
10. Retirement Living TV Presents Sex, Drugs and Rock N Roll
11. AviaraDx Presents at 2007 BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Clinical Trial Concluded For New Wrinkle Treatment 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 3Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 2Health News:The Palomino Group Announces Launch of Meeting Support Services Business Unit 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:Thomson Reuters Publishes CMR International's 2008 Pharmaceutical R&D Factbook, Now Available for the First Time Online 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:California Supreme Court Gay-Marriage Ruling Reinforces Top Bay Area Fertility Specialists' Support for Same-Sex Couples 2
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Steaz Launches Organic Zero Calorie Sparkling Line 59893 1Steaz Launches Organic Zero Calorie Sparkling Line 59893 2Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 1Henry Schein to Webcast Third Quarter 2009 Conference Call Wednesday November 4 at 10 A M EST 59891 2Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2